anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GnRH stimulation is the gold standard to distinguish between isolated premature thelarche (PT) and CPP. However, intravenous GnRH for testing is not fully available in all countries. To evaluate the diagnostic accuracy of a novel Triptorelin-test in the assessment of CPP compared to the GnRH test, a validation study was performed. Girls who presented thelarche with accelerated growth and/or advanced bone age were included. All girls underwent the two tests in a randomized order. CPP was ascertained according to LH response under GnRH (gold standard test).
Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
This retrospective study was performed by obtaining medical records of patients who underwent lumbar spinal MRI between September 2019 and February 2020. After the application of exclusion criteria 955 patients determined between the specified dates. These patients were called by phone to be questioned about their smoking status and whether they were working in heavy work and whether they were athletes. Heavy workers and athletes were also excluded from the study and a total of 360 patients whose smoking status information could be obtained were included in the study.The patients were grouped according to their smoking status as "current smoker", "former smoker", "non-smoker" and "passive smoker". The cumulative smoking dose for current and former smokers was calculated in terms of pack-years and categorized further into two subgroups: smoked ≤9 pack-years or \>9 pack-years. The number of pack-years was calculated by dividing the number of cigarettes consumed per day by 20 and multiplying by the years that the patient had smoked. Age, gender, weight, and height were recorded, and body mass index (BMI) was calculated as weight/(height)2. Lumbar spinal MRI was performed using a 1.5 Tesla imaging system (General Electric Healthcare, Milwaukee, WI), using the following settings: amplitude: 44 mT/m; slew rate gradient configuration: 200 T/m/s. MRI images were evaluated using a GE Advantage Workstation (GE Healthcare, Buc, France) and Volume Share software v.7.0. The lumbar lordosis angle was measured and the lumbar intervertebral discs were evaluated by Pfirrmann disc degeneration grading system using sagittal T2-weighted MR images (TR/TE: 2500/85 ms, matrix: 320x224, slice thickness: 4 mm, FOV: 32) (23). The degree of degeneration was classified into five grades with Grades IV and V considered as "severe disc degeneration". Radiologist reviewing the MRI studies was blinded to the smoking status of the participants.
One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring \<3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.
PCT No. PCT/DK94/00271 Sec. 371 Date Nov. 7, 1995 Sec. 102(e) Date Nov. 7, 1995 PCT Filed Jul. 1, 1994 PCT Pub. No. WO95/02577 PCT Pub. Date Jan. 26, 1995The present invention relates to compounds of formula in which formula X is hydrogen or hydroxy; R1 and R2, which may be the same or different, stand for hydrogen or C1-C4 hydrocarbyl; or R1 and R2, taken together with the carbon atom bearing the group X, can form a C3-C8 carbocyclic ring; Q is a single bond or a C1-C4 hydrocarbylene diradical; R1, R2 and/or Q may be optionally substituted with one or more fluorine atoms; and prodrugs of formula in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo. The compounds show antiinflammatory and immunomodulating effects as well as stong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells.
The focus of this study is to use Structured Treatment Interruption (STI) as an approach to auto-immunization. The STI management schema is based on current understanding of HIV-1 viral dynamics, pharmacology of available antiretroviral medications, and HIV-specific host responses. This is a Phase II trial to provide preliminary data on the feasibility and possible efficacy of using STI to enhance immune-based control of HIV-1 replication. A steady state HIV-1 viral load determined from historical tests prior to initiating highly active antiretroviral therapy (HAART) will be compared to the steady state viral load post-STI. HIV-1 specific CD4 and CD8 cell responses will be measured before and after the period of STI management and HIV-1 specific CD8 cell maturational phenotype will be assessed and correlated with ability to control viral replication.

Adolescents and young adults who have either had sustained viral suppression on HAART for at least 2 years or who have had sustained viral suppression from 3 to 6 months will be eligible for this study. Participants will have 12 weeks of HAART followed by 2 to 4 weeks of treatment interruption. Participants will undergo three rounds of this regimen. After the third STI, participants will have an additional 12 weeks of HAART and then stop therapy. Participants will be monitored off HAART for up to 20 weeks. During this time, if there is evidence of HIV progression (two consecutive viral loads exceeding 10,000 copies/ml; two consecutive CD4 cell counts under 350 cells/microL; two consecutive CD4 percentages less than 15%; or two consecutive CD4 cell counts less than 50% of baseline), standard continuous antiretroviral therapy will be reinstituted. Plasma HIV RNA will be tested monthly during therapy and weekly while subjects are off treatment. Immunologic studies are monthly throughout the study. Participants will be involved in the study for approximately 2 years.
Veterinary compositions which are non-aqueous creams or pastes suitable for intramammary injection, comprise a suspension of penicillin and/or streptomycin in admixture with a suitable dispersing agent and not less than 30 per cent by weight of a suitable mineral oil.  The penicillin may be a natural penicillin, e.g. penicillin G, or a synthetic penicillin, e.g. penicillin V, optionally in the form of a salt thereof, e.g. the sodium, calcium, potassium or procaine salt.  The streptomycin may be present as such or as dihydrostreptomycin, optionally in the form of a salt thereof, e.g. sulphate or hydrochloride, or as a complex thereof, e.g. with calcium chloride.  The mineral oil is defined as being mixtures of hydrocarbon oils, e.g. liquid and light liquid paraffin or petroleum jellies, which may be thickened by the addition of white or yellow soft paraffins, or aluminium palmitate.  The dispersing agent is defined as having a hydrophilic-lipophilic balance of between 9.5 and 10.5 and may be a partial ester of the common fatty acids, e.g. lauric, palmitic, stearic or oleic acid, and hexital anhydrides, e.g. hexitans or hexides derived from sorbitol, the corresponding condensation product of these partial esters with ethylene oxide, or mixtures thereof, polyoxyethylene sorbitan monostearate, tristearate, mono-oleate, pentalaurate, hexa-oleate, polyoxyethylene lauryl alcohol, polyoxyethylene cetyl alcohol, or polyoxyethylene sorbitol laurate, or mixtures thereof.  The dispersing agent may be present between 0.5 and 10 per cent by weight of the composition.
PURPOSE:To reduce communication quantity between management parts and the operation load of an additional information management part in a system which is provided with picture management parts and the additional information management part and which receives a processing request in the additional information management part. CONSTITUTION:One additional information management part 10 is connected to LAN 1 and the plural picture management parts 11a-11d are connected to LAN 1 and 2. A modality 4 and a work station 5 are connected to LAN 1 and 2. The additional information management part 10 receives a picture registration request, issues a logical address (identification code) and returns it with a transfer destination to the modality 4. At that time, the retrieval table 24 of characteristic information and the logical address is generated. The picture management part 11a (...11d) registers a picture and generates the address table 32 of the logical address and a physical address. When the additional information management part 10 receives an access request, it retrieves the logical address and transmits the logical address and a request content to the picture management part 11a (...11d). The picture management part retrieves the physical address from the table 32 and executes a processing.
Liquid hydrocarbons are removed from waste pits where they exist in a free state, via physical or mechanical methods (with heat or otherwise). The pits are blinded and closed once the areas altered by confinement of the selected material have been cleaned, using clean granular material from nearby quarries or gravel pits. The bituminous mixture or liquid oil-bearing material extracted from the pits is filitered and stabilized, using heat or chemicals, by means of a Portable Crude Stabilizer Tank. After filtering thick emulsion contaminated solid debris, the remaining oil-bearing mass is preheated and immediately liquefied in a tank, using preheating coils and, optionally, injecting chemicals. Final filtration and breaking the oil-bearing emulsion down into its components occurs in a closed horizontal or tilted receptacle, lined with thermal insulation, with diameters ranging form 43 to 86 inches, and a total length of around 15, 30 or 45 feet (varying in accordance with the required treatment speed). The receptacle operates at different internal pressures, starting with atmospheric pressure, and at temperatures ranging from ambient temperature to a few degrees below steam temperature, so as not to exceed the boiling point.
To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
The invention provides an intelligent selection method and an intelligent selection device for a detection injury classification method, which solve the technical problem that the existing detection injury means cannot adapt to large-scale, wide-area and long-period detection injury classification. The method comprises the following steps: forming a training data set according to real injury detection data of the whole period of injury detection classification; training the artificial neural network through a training data set to form an intelligent selection model of the injury detection method; in the whole period of the injury detection classification, an intelligent selection model of the injury detection method is activated according to the dimensional change of the data to receive the current wounded information, and the injury detection classification method of the current stage is determined. And selecting a detection injury classification method according to the data acquisition state. The selection of the injury detection classification method in the current stage can fully process the current wounded state data, and can be switched to the adaptive injury detection classification method based on the stage data. And the reliability of the classification evaluation result of the detection injury is ensured. The selection of the examination injury classification method based on the knowledge rules of the professional doctor is effectively promoted.
Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature \<38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC \> 0,5 x10\^9/L), whichever comes first.
This study uses a placebo-controlled, crossover design to investigate the effect of modafinil (100 mg, p.o.), methylphenidate (20 mg, p.o.), and lorazepam (1 mg, p.o.) in 15 healthy male volunteers. The acute effect of the medications will be measured by MEG, EEG and simple cognition testing. Study procedures will be performed over 5 separate days. During an initial screening visit, Study Day 1, subjects will consent to enroll and undergo clinical evaluation sufficient to determine they are eligible to participate in the study. Upon qualification and enrollment, subjects will be randomly assigned to receive either placebo or one of the active medications on Study Days 2 - 5. Medications or placebo will be administered orally. Subjects will arrive at the MEG center in the morning on Study Day 2 and baseline MEG and EEG scans will be performed along with baseline cognition testing. The medication or placebo will be administered immediately following the baseline scans and cognition testing. Additional MEG and EEG scans will be conducted 2, 4, and 6 hours after medication or placebo administration. On Study Days 3 - 5, subjects will undergo identical procedures but will be crossed over to receive the alternate medication or placebo.
Cholecystectomy is a commonly performed procedure in general surgical practice, and with advancements in technology, it is widely conducted using the laparoscopic method. Despite the decreasing trend in open surgical procedures with increasing experience and technological developments, the literature reports conversion to open surgery in laparoscopic cholecystectomy ranging from 2% to 15%. Although some studies exist regarding patient groups at risk of conversion to open surgery, the current literature is insufficient to draw a clear conclusion on this matter. This study aims to evaluate risk factors for conversion to open surgery by examining cases of laparoscopically initiated cholecystectomy.

The study will be conducted retrospectively by reviewing archive records. Patients operated for cholecystectomy will be included. Patients that open surgical method used from start will be excluded from study. Age, comorbidities (ASA score), laboratory findings (leukocyte count and CRP), imaging findings (abdominal ultrasound, CT, or MRI), history of previous abdominal surgery, history of ERCP, and history of pancreatitis will be evaluated. Laparoscopic cholecystectomy cases will be compared with open-conversion cholecystectomies to assess factors influencing the conversion.
Cefuroxime, USP is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following structural formula: 

The molecular formula is C16H15N4NaO8S, representing a molecular weight of 446.4.

Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. 

Cefuroxime for Injection, USP in sterile crystalline form is supplied as Pharmacy Bulk Package equivalent to 7.5 g of cefuroxime as cefuroxime sodium. Solutions of Cefuroxime for Injection, USP range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5.

A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. FURTHER DILUTION IS REQUIRED BEFORE USE.
PURPOSE: Recognizing that receiving healthcare can be time intensive and burdensome, time toxicity has been conceptualized as the time spent by patients seeking healthcare. This study investigates the association between age at diagnosis and time toxicity for patients with Metastatic Breast Cancer (MBC) and identifies major components of care that confer the greatest time toxicity.
METHODS: We conducted a retrospective cohort study among patients with MBC aged 67 or older using the SEER-Medicare database. We assessed time toxicity using the number of encounter days patients interacted with the healthcare system per 100 days, within the first year of starting cancer treatment. We used a Poisson model to analyze the association between age and encounter days, adjusting for clinical and sociodemographic factors. We stratified the mean encounter days for each age cohort by treatment types.
FINDINGS: The final sample included 2949 patients; 51.4% were between 70 and 79 years old, and 81.3% were white. Although unadjusted analysis showed an association between older age and more encounter days (Rate Ratio (RR) 1.12; 95% CI 1.02, 1.22), there was no significant association after adjusting for comorbidities and treatment type. Patients with more than three comorbidities had significantly higher encounter days compared to those without comorbidities [RR 1.36 (95% CI 1.26, 1.46)]. Receipt of radiotherapy [RR: 1.45 95% CI (1.37, 1.54)] was associated with more encounter days compared to not receiving radiotherapy, while receipt of bone-modifying agents was associated with fewer encounter days compared to not using Bone modifying agents [RR 0.75 (95% CI 0.70, 0.79)].
CONCLUSION: Our study identified comorbidities and cancer treatment modality, including radiotherapy, as the factors affecting time toxicity in older patients with MBC. Assessment of an individual's comorbid medical conditions and types of treatment planned are crucial to understanding age-related impacts on encounter days and to support shared decision making in older patients.
PURPOSE:To obtain a cell line for preparing hybridoma derived by mutation from tumor cells other than a tumor cell derived from marrow cell. CONSTITUTION:A cancerous cell is irradiated with ultraviolet rays or provided with a mutagen such as ethylmethanesulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, etc. in a proper dose or amount depending upon its kind, the cell is transferred to a medium containing 8-azaguanidine, to develop a strain resistant to 8-azaguanidine. The use of HAT selection is then examined. The cell is cultivated, the medium is removed by centrifugation, the cell is washed with a HAT medium, and transferred to the same HAT medium. It is observed for several days, and life or death is judged.
This invention provides a fabrication and preparation method for collagen and collagen peptide from oceanic fish skin and/or discarded waste fish products, which mainly uses oceanic fish skin and/or discarded waste fish products as raw materials. The raw material is washed, cleaned, and ground, and then added with extraction fluid, followed by pressurizing and heating process. After that, it is added with water-soluble enzyme for enzyme treatment, followed by centrifugal filtration. After previous treatments, the top layer liquid of the water solution is taken out and added with de-colorant, and then fabricated into the collagen in dried powder. Moreover, after the top layer liquid is taken out, it is treated with sodium chloride deposition and separation to obtain solidified substance, which is dissolved with pure water and treated with ultra filtration process to remove the impurities to obtain extraction liquid, and then fabricated into the collagen in dried powder with high purity. Besides, the extraction liquid can be added with the water-soluble enzyme for performing second-stage enzyme process to fabricate into the collagen peptide in dried powder with high purity. By this way, collagen and collagen peptide with high production rate, high purity, and low pollution can be made from the oceanic fish skin and/or discarded waste fish products.
Systems and methods for monitoring subjects for a variety of hereditary cancers include obtaining an electronic medical record associated with a subject. Data items are extracted from the medical record of the subject. The data items describe information of the electronic medical record and include at least an age of the subject as well as a cancer history of family of the subject. The data items are run against various filter sets. Each filter set is associated with a different hereditary cancer and has a corresponding alert. When a filter is fired, due to triggering the conditions of the filter, the subject is deemed to have an actionable risk of the hereditary cancer associated with the corresponding filter set. The alert, that includes the filter that is fired, is communicated accordingly.
BACKGROUND: Hip periprosthetic fractures (PPFs) after primary total hip arthroplasty are increasing with the number of primary implants and aging population. Mortality has been reported up to 34% at 1-year. The aim of this study was to evaluate the association of Clinical Frailty Scale (CFS) and 1-year mortality, complication rate, and length of stay (LOS) in surgically managed hip PPFs.
METHODS: This was a retrospective study of prospectively collected data from January 2008 to January 2021. A total of 282 surgically managed hip PPFs were identified. Mean age was 79 years (range, 42 to 106). Preoperative scores were analyzed through linear regression to identify significant association with mortality, complication and LOS. Receiver operating characteristic curve and Area Under the Curve (AUC) were generated to evaluate the quality of the models and the discriminatory ability of each clinical score. Significance was considered at P values < .05.
RESULTS: Mortality was 7.8% at 3-months and 15.7% at 1-year. Complication rate requiring surgery was 19.5% and mean LOS was 8.9 ± 7 days. The CFS was significantly associated with 3-month (odds ratio 2.23, P < .001) and 1-year mortality (odds ratio 2.01, P < .001). The receiver operating characteristic curve test for 1-year mortality showed a greater AUC for the CFS when compared with American Society for Anesthesiologists score and age-adjusted Charlson Comorbidity Index (AUC 0.80 versus 0.68 versus 0.72, respectively).
CONCLUSIONS: Frailty is a syndrome with increased risk of mortality after surgically managed PPF. The CFS can be easily assessed at the time of admission and could be considered as a strong and reliable predictor of 1-year mortality with a greater AUC than the conventionally used American Society for Anesthesiologists score.